Purpose
Dose-dense regimens have been shown to
improve outcome when given as adjuvant therapy to patients with breast
cancer compared with their three weekly counterparts. We investigated
the feasibility of a dose-dense regimen with carboplatin/paclitaxel
followed by pegfilgrastim in patients with advanced ovarian cancer. We
also investigated the toxicities including the percentage of patients
with grade 2 or greater peripheral neurotoxicity and the clinical
response of this regimen.
Conclusion
Dose-dense
carboplatin/paclitaxel appears to be effective. However, based on dose
limiting toxicities occurring when administering 6 cycles of treatment,
it is not feasible. Given the neuropathy and thrombocytopenia, we do not
recommend 6 cycles of this regimen without modification.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.